Patrick J Leavey

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi request reprint Graduate medical education changes: yes we can or enough already?
    Patrick J Leavey
    Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center Dallas, 5323 Harry Hines Blvd, Dallas, TX 75290 9063, USA
    Pediatr Blood Cancer 59:1168-72. 2012
  2. pmc Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group
    Patrick J Leavey
    Department of Pediatrics, University of Texas Southwestern Medical Center and Children s Medical Center Dallas, TX 75390 9063, USA
    Pediatr Blood Cancer 51:334-8. 2008
  3. ncbi request reprint Skip metastasis in osteosarcoma
    Patrick J Leavey
    Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, TX 75390 9063, USA
    J Pediatr Hematol Oncol 25:806-8. 2003
  4. doi request reprint Ewing sarcoma: prognostic criteria, outcomes and future treatment
    Patrick J Leavey
    Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9063, USA
    Expert Rev Anticancer Ther 8:617-24. 2008
  5. ncbi request reprint KAI-1 expression in pediatric high-grade osteosarcoma
    Patrick J Leavey
    Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9063, USA
    Pediatr Dev Pathol 9:219-24. 2006
  6. ncbi request reprint Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma
    David S Dickens
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Hematol Oncol 25:282-5. 2003
  7. doi request reprint Predictive value of interleukin-5 and monocyte chemotactic protein-1 for bacteremia in children with febrile neutropenia
    Victor M Aquino
    Department of Pediatrics, Divisions of Pediatric Hematology and Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75290 9063, USA
    J Pediatr Hematol Oncol 34:e241-5. 2012
  8. ncbi request reprint Effective removal of methotrexate by high-flux hemodialysis
    Jeffrey M Saland
    Department of Pediatrics, The Mount Sinai School of Medicine, One Gustave L Levy Place Box 1664, NY 10029 6574, USA
    Pediatr Nephrol 17:825-9. 2002
  9. ncbi request reprint Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors
    Daniel C Bowers
    Department of Pediatrics, UT Southwestern Medical Center at Dallas, Dallas, Texas 75390 9063, USA
    Pediatr Blood Cancer 42:93-8. 2004
  10. ncbi request reprint Extracorporeal membrane oxygenation (ECMO) initiation without intubation in two children with mediastinal malignancy
    Jonathan E Wickiser
    Department of Pediatrics, Division of Pediatric Hematology Oncology, University of Texas Southwestern Medical Center at Dallas and Children s Medical Center of Dallas, Dallas, Texas, USA
    Pediatr Blood Cancer 49:751-4. 2007

Detail Information

Publications13

  1. doi request reprint Graduate medical education changes: yes we can or enough already?
    Patrick J Leavey
    Division of Pediatric Hematology Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center Dallas, 5323 Harry Hines Blvd, Dallas, TX 75290 9063, USA
    Pediatr Blood Cancer 59:1168-72. 2012
    ..Pediatr Blood Cancer 2012; 59: 1168-1172. © 2012 Wiley Periodicals, Inc...
  2. pmc Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group
    Patrick J Leavey
    Department of Pediatrics, University of Texas Southwestern Medical Center and Children s Medical Center Dallas, TX 75390 9063, USA
    Pediatr Blood Cancer 51:334-8. 2008
    ..The prognosis for patients with recurrent Ewing sarcoma (EWS) is very poor with 5-year survival of 13%...
  3. ncbi request reprint Skip metastasis in osteosarcoma
    Patrick J Leavey
    Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, TX 75390 9063, USA
    J Pediatr Hematol Oncol 25:806-8. 2003
    ..The patients were treated with adjuvant chemotherapy and radical surgical resection. Both are alive and free of disease 3 and 6 years from diagnosis...
  4. doi request reprint Ewing sarcoma: prognostic criteria, outcomes and future treatment
    Patrick J Leavey
    Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9063, USA
    Expert Rev Anticancer Ther 8:617-24. 2008
    ..However, recent evidence supporting novel cytotoxic therapy, antiangiogenic therapy, and receptor-targeted therapy provides reason for optimism for patients with high-risk disease...
  5. ncbi request reprint KAI-1 expression in pediatric high-grade osteosarcoma
    Patrick J Leavey
    Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX 75390 9063, USA
    Pediatr Dev Pathol 9:219-24. 2006
    ..This difference was not statistically significant. We conclude that KAI-1 is expressed in a proportion of high-grade osteosarcoma but is not of clinical significance and cannot be used to stratify treatment groups for these patients...
  6. ncbi request reprint Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma
    David S Dickens
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Hematol Oncol 25:282-5. 2003
    ..COX-2 overexpression correlates with more aggressive disease in a variety of adult solid tumors...
  7. doi request reprint Predictive value of interleukin-5 and monocyte chemotactic protein-1 for bacteremia in children with febrile neutropenia
    Victor M Aquino
    Department of Pediatrics, Divisions of Pediatric Hematology and Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75290 9063, USA
    J Pediatr Hematol Oncol 34:e241-5. 2012
    ..Prospective studies should be undertaken to determine whether these parameters retain predictive value in a larger series of patients and can select children for outpatient management or early discharge...
  8. ncbi request reprint Effective removal of methotrexate by high-flux hemodialysis
    Jeffrey M Saland
    Department of Pediatrics, The Mount Sinai School of Medicine, One Gustave L Levy Place Box 1664, NY 10029 6574, USA
    Pediatr Nephrol 17:825-9. 2002
    ..Therapy is indicated in cases where compassionate use of CPDG(2) may not be available, or while awaiting its delivery...
  9. ncbi request reprint Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors
    Daniel C Bowers
    Department of Pediatrics, UT Southwestern Medical Center at Dallas, Dallas, Texas 75390 9063, USA
    Pediatr Blood Cancer 42:93-8. 2004
    ..To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors...
  10. ncbi request reprint Extracorporeal membrane oxygenation (ECMO) initiation without intubation in two children with mediastinal malignancy
    Jonathan E Wickiser
    Department of Pediatrics, Division of Pediatric Hematology Oncology, University of Texas Southwestern Medical Center at Dallas and Children s Medical Center of Dallas, Dallas, Texas, USA
    Pediatr Blood Cancer 49:751-4. 2007
    ..Results are presented on the use of ECMO as a primary means of stabilizing a pediatric patient with a critical mediastinal mass, thus providing another management strategy for this difficult situation...
  11. ncbi request reprint The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma
    Dan Ye
    Division of Hematology Oncology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    J Pediatr Hematol Oncol 25:459-66. 2003
    ..Recently, the human epidermal growth factor (HER)-2 receptor, which plays an important role in the biology of certain epithelial cancers, has been implicated in ES tumor cell line growth and chemosensitivity...
  12. ncbi request reprint Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma
    Patrick J Leavey
    Department of Pediatrics, Division of Hematology Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
    Pediatr Hematol Oncol 19:483-9. 2002
    ..The use of HD-MTX should be carefully planned so that it does not decrease its dose intensity or that of other effective agents...
  13. ncbi request reprint Brief report: successful therapy of a patient with infantile generalized myofibromatosis
    Michael Day
    Southwestern Medical School, University of Texas Southwestern Medical Center at Dallas and Children s Medical Center of Dallas, USA
    Med Pediatr Oncol 38:371-3. 2002